AI assistant
Sending…
Insight Molecular Diagnostics Inc. — Director's Dealing 2016
Aug 30, 2016
34238_dirs_2016-08-30_453662e7-255b-4060-9f5d-01c9c5148809.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: OncoCyte Corp (OCX)
CIK: 0001642380
Period of Report: 2016-08-29
Reporting Person: BAILEY DON M (Director)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2016-08-29 | Option to Purchase Common Stock | $4.02 | A | 20000 | Acquired | 2026-08-28 | Common Stock (20000) | Direct |
Footnotes
F1: Will become exercisable in four equal installments at the end of each calendar quarter based upon continued service on the board of directors from the date of grant.
More from Insight Molecular Diagnostics Inc.
Annual Report
2026
Apr 30
Regulatory Filings
2026
Apr 30
Regulatory Filings
2026
Feb 26
Director's Dealing
2026
Feb 12
Major Shareholding Notification
2026
Feb 12
Regulatory Filings
2026
Feb 12
Regulatory Filings
2026
Feb 11
Regulatory Filings
2026
Feb 11
Director's Dealing
2025
Nov 13
Interim / Quarterly Report
2025
Nov 10